Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro

The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2007-03, Vol.331 (2), p.224-227
Hauptverfasser: HENGST, V, OUSSOREN, C, KISSEL, T, STORM, G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 227
container_issue 2
container_start_page 224
container_title International journal of pharmaceutics
container_volume 331
creator HENGST, V
OUSSOREN, C
KISSEL, T
STORM, G
description The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone.
doi_str_mv 10.1016/j.ijpharm.2006.11.024
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69004186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69004186</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-7e615121dcc22215ace3255db2c1639adf3fd0c74fcdc6fb6c26b7bfdd3594913</originalsourceid><addsrcrecordid>eNpF0MFO3DAQBmCralUW2kdo5Us5keCxYyc5tggKEhIXel5NbIf1KrFd24u6vfTVCWURh9FIo0__jIaQL8BqYKDOt7Xbxg2mueaMqRqgZrx5R1bQtaISTavekxUTbVdJaMUROc55yxbIQXwkR9CCZALUivz7EbylBdODLc4_0BiK9cXhRMNIB5fjJjyXx2KrF2UNnVwMOcw205hsxITFBX9G9XIO6mKT-_t_QtEbutmbFP7sMS6jYpdIb573OE8fXUnhE_kw4pTt50M_Ib-uLu8vrqvbu583F99vq8hFX6rWKpDAwWjNOQeJ2goupRm4BiV6NKMYDdNtM2qj1TgozdXQDqMxQvZND-KEnL7kxhR-72wu69llbacJvQ27vFY9Yw10aoFfD3A3zNasY3Izpv369WUL-HYAmDVOY0KvXX5znew6qZh4AhFogaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69004186</pqid></control><display><type>article</type><title>Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>HENGST, V ; OUSSOREN, C ; KISSEL, T ; STORM, G</creator><creatorcontrib>HENGST, V ; OUSSOREN, C ; KISSEL, T ; STORM, G</creatorcontrib><description>The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2006.11.024</identifier><identifier>PMID: 17150316</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier</publisher><subject>Binding Sites ; Biological and medical sciences ; Bone and Bones - metabolism ; Bone Diseases - drug therapy ; Cholesterol Esters - metabolism ; Diphosphonates - metabolism ; Drug Delivery Systems - methods ; Durapatite - metabolism ; General pharmacology ; Liposomes - pharmacokinetics ; Liposomes - therapeutic use ; Medical sciences ; Particle Size ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments</subject><ispartof>International journal of pharmaceutics, 2007-03, Vol.331 (2), p.224-227</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18588560$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17150316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HENGST, V</creatorcontrib><creatorcontrib>OUSSOREN, C</creatorcontrib><creatorcontrib>KISSEL, T</creatorcontrib><creatorcontrib>STORM, G</creatorcontrib><title>Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone.</description><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Bone and Bones - metabolism</subject><subject>Bone Diseases - drug therapy</subject><subject>Cholesterol Esters - metabolism</subject><subject>Diphosphonates - metabolism</subject><subject>Drug Delivery Systems - methods</subject><subject>Durapatite - metabolism</subject><subject>General pharmacology</subject><subject>Liposomes - pharmacokinetics</subject><subject>Liposomes - therapeutic use</subject><subject>Medical sciences</subject><subject>Particle Size</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0MFO3DAQBmCralUW2kdo5Us5keCxYyc5tggKEhIXel5NbIf1KrFd24u6vfTVCWURh9FIo0__jIaQL8BqYKDOt7Xbxg2mueaMqRqgZrx5R1bQtaISTavekxUTbVdJaMUROc55yxbIQXwkR9CCZALUivz7EbylBdODLc4_0BiK9cXhRMNIB5fjJjyXx2KrF2UNnVwMOcw205hsxITFBX9G9XIO6mKT-_t_QtEbutmbFP7sMS6jYpdIb573OE8fXUnhE_kw4pTt50M_Ib-uLu8vrqvbu583F99vq8hFX6rWKpDAwWjNOQeJ2goupRm4BiV6NKMYDdNtM2qj1TgozdXQDqMxQvZND-KEnL7kxhR-72wu69llbacJvQ27vFY9Yw10aoFfD3A3zNasY3Izpv369WUL-HYAmDVOY0KvXX5znew6qZh4AhFogaQ</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>HENGST, V</creator><creator>OUSSOREN, C</creator><creator>KISSEL, T</creator><creator>STORM, G</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20070301</creationdate><title>Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro</title><author>HENGST, V ; OUSSOREN, C ; KISSEL, T ; STORM, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-7e615121dcc22215ace3255db2c1639adf3fd0c74fcdc6fb6c26b7bfdd3594913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Bone and Bones - metabolism</topic><topic>Bone Diseases - drug therapy</topic><topic>Cholesterol Esters - metabolism</topic><topic>Diphosphonates - metabolism</topic><topic>Drug Delivery Systems - methods</topic><topic>Durapatite - metabolism</topic><topic>General pharmacology</topic><topic>Liposomes - pharmacokinetics</topic><topic>Liposomes - therapeutic use</topic><topic>Medical sciences</topic><topic>Particle Size</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HENGST, V</creatorcontrib><creatorcontrib>OUSSOREN, C</creatorcontrib><creatorcontrib>KISSEL, T</creatorcontrib><creatorcontrib>STORM, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HENGST, V</au><au>OUSSOREN, C</au><au>KISSEL, T</au><au>STORM, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2007-03-01</date><risdate>2007</risdate><volume>331</volume><issue>2</issue><spage>224</spage><epage>227</epage><pages>224-227</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone.</abstract><cop>Amsterdam</cop><pub>Elsevier</pub><pmid>17150316</pmid><doi>10.1016/j.ijpharm.2006.11.024</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2007-03, Vol.331 (2), p.224-227
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_69004186
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Binding Sites
Biological and medical sciences
Bone and Bones - metabolism
Bone Diseases - drug therapy
Cholesterol Esters - metabolism
Diphosphonates - metabolism
Drug Delivery Systems - methods
Durapatite - metabolism
General pharmacology
Liposomes - pharmacokinetics
Liposomes - therapeutic use
Medical sciences
Particle Size
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
title Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T10%3A07%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20targeting%20potential%20of%20bisphosphonate-targeted%20liposomes%20preparation,%20characterization%20and%20hydroxyapatite%20binding%20in%20vitro&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=HENGST,%20V&rft.date=2007-03-01&rft.volume=331&rft.issue=2&rft.spage=224&rft.epage=227&rft.pages=224-227&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2006.11.024&rft_dat=%3Cproquest_pubme%3E69004186%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69004186&rft_id=info:pmid/17150316&rfr_iscdi=true